Close Menu

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) issued a draft guidance on Friday stating that it does not recommend abemaciclib (Eli Lily's Verzenio) for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.